Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Study of Fedratinib in Myelofibrosis
NCT01420770Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fedratinib in myelofibrosis (MF), sponsored by Bristol Myers Squibb. Started Aug 2011; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01420770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420770.